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http:WHAT THIS PAPER ADDS
Arterial peak ﬂow is a quick and simple functional magnetic resonance imaging-derived measure that can be
used to objectively quantify vascular status and to monitor therapy in patients with peripheral arterial disease.
In clinical practice, it would be desirable to have a standardized arterial segment to measure the arterial peak
ﬂow, comparable to, for example, ankle-brachial index measurements, independent of the location of
obstructive arterial lesions, but with the greatest likelihood to differentiate between a diseased and healthy
arterial vasculature and with well-known normative values.Objective: To determine the best location to measure the arterial peak ﬂow (APF) in patients with peripheral
arterial disease in order to facilitate clinical standardization.
Methods: Two hundred and ﬁfty-nine patients with varying degrees of peripheral artery disease (PAD) and 48
patients without PAD were included. All patients underwent magnetic resonance phase-contrast imaging of the
common femoral artery (CFA), superﬁcial femoral artery (SFA), and popliteal artery (PA). APF values of patients
with PAD were compared with patients with no PAD. The discriminative ability to identify PAD was evaluated by
means of receivereoperator characteristic curves and the corresponding areas under the curve (AUC).
Results: Mean APF values in patients with PAD were reduced by 42%, 55% and 59% compared with non-PAD
patients for the CFA, SFA, and PA, respectively (p < .01). The AUC’s were 0.84, 0.92, and 0.93 for the CFA, SFA,
and PA, respectively.
Conclusion: The APF measured at the level of the PA shows the largest differences between patients with PAD
and patients with no PAD and the best discriminative ability compared with the APF acquired in the CFA or SFA.
The PA seems to be the most suitable level for standardized ﬂow measurements in patients with PAD in order to
obtain relevant functional information about the vascular status.
 2014 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.
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Magnetic resonance angiography (MRA) is a highly accurate
noninvasive diagnostic imaging method for the morpho-
logical evaluation of the peripheral arteries in patients with
peripheral arterial disease (PAD).1e4 Clinically, owing to high
costs and limited availability, MRA is mainly applied in the
setting of treatment planning and/or therapy monitoring.
Nevertheless, given the progressive nature of PAD,
increasing numbers of patients undergo multiple MRA ex-
aminations during their lifetime for treatment planningof original article: http://dx.doi.org/10.1016/j.ejvs.2014.05.010
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//dx.doi.org/10.1016/j.ejvs.2014.04.022and/or therapy monitoring. For these patients, a fast and
simple functional magnetic resonance imaging (MRI)-
derived measure, such as the arterial peak ﬂow (APF), which
is suitable to objectively quantify the vascular status and to
monitor the progression of PAD over time, might be a
valuable addition to MRA.5e7 Numerous other noninvasive
functional diagnostic tools are available for this purpose,
such as ankle-brachial pressure index (ABI), duplex ultra-
sonography, and laser Doppler measurements.8e11 Howev-
er, APF measurements have the advantage of being quick,
reproducible, and highly automated, with acquisition times
well below 1 minute, and can easily be added to existing
MRA protocols to obtain the functional vascular status
together with morphologic information during the same
examination.5,6,12e14
Previous studies have demonstrated good reproducibility
for APF measurements and lower APF values in patients
with PAD compared with healthy controls.5e7 For clinical
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arterial location to measure the APF, comparable to ABI
measurements, independent of the location of obstructive
arterial lesions, but with good ability to differentiate be-
tween a diseased and healthy arterial vasculature, and with
well-known reference values. Therefore, in this preliminary
study the APF was acquired at three distinctive and stan-
dardized arterial positions in a large group of patients with
PAD and patients without PAD with the purpose of deter-
mining the optimal location that best differentiates be-
tween patients with PAD and those without.
METHODS
Study population
MR cine phase-contrast imaging ﬂow measurements are a
standard addition to contrast-enhanced MRA (CE-MRA) at
Maastricht University Medical Center (MUMC) in all pa-
tients scheduled for CE-MRA of peripheral arteries. The
ethics committee of MUMC waived the need for informed
consent from patients, as ﬂow measurements are part of
the standard imaging protocol at MUMC. Data were retro-
spectively analyzed anonymously. Patients with (partial)
lower extremity amputations were excluded from the study.
Otherwise, there were no exclusion criteria. Patients
referred for CE-MRA of the peripheral arterial tree to rule
out deep vein thrombosis (DVT) or in the preoperative
workup for reconstructive surgery using lower extremity
tissue ﬂaps with no clinical symptoms of PAD or signs of
PAD on CE-MRA were used as the reference. Patient char-
acteristics were retrieved from the patient records and are
summarized in Table 1.MRI protocol
All patients underwent a three-station CE-MRA protocol of
the peripheral arteries,15 followed by quantitative MR cine
phase-contrast imaging ﬂow measurements at three
distinctive arterial positions as described below. Flow data
were used to obtain the APF in patients with PAD and inTable 1. Patient characteristics.
Patients
with PAD
Patients
without PAD
Number 259 48
Men (%)/women (%) 147 (57)/112 (43) 23 (48)/25 (52)
Age, years (mean  SD) 67  13.1 53  16.4*
Heart rate, bpm
(mean  SD)
71  13 75  14
Bodyweight, kg
(mean  SD)
77.1  15.1 75.7  16.4
IC/CI (%) 137 (53)/122 (47) e
Diabetics (%) 120 (54)b,a 5 (13)b
Note. PAD ¼ peripheral arterial disease; bpm ¼ beats per minute;
IC ¼ intermittent claudication; CI ¼ critical ischemia.*p < .01.
a Diabetic status could only be retrieved in 221/259 patients with
PAD.
b Diabetic status could only be retrieved in 38/48 patients without
PAD.those without it.16 All examinations were performed using a
1.5-T MRI system (Intera, Philips Medical Systems, Best, the
Netherlands). Patients were imaged in the supine position
and were in this position for approximately 30 minutes
before the ﬂow measurements were started. During this
period, the CE-MRA examination was performed using a
ﬁxed dose of 10-mL gadofosveset trisodium (Ablavar;
Lantheus Medical Imaging, Billerica, MA, USA) as contrast
agent.6,17
CE-MRA. A three-station three-dimensional gradient-echo
(fast ﬁeld echo) MRA sequence was performed as previ-
ously described.2,15
Flow MRI. For quantitative cine phase-contrast imaging a
two-dimensional gradient-echo (fast ﬁeld echo) scan tech-
nique was used. Measurements were performed at the
level of the proximal common femoral artery (CFA), the
proximal superﬁcial femoral artery (SFA), and the P2-
segment of the popliteal artery (PA) (Fig. 1). Parallel imag-
ing (sensitivity encoding, SENSE) was applied to reduce scan
time (SENSE acceleration factor 2 in the anterior-posterior
direction).18 At a mean heart rate of 60 beats per minute,
the nominal acquisition time was 1 minute.Angiographic reading
All CE-MRA datasets were analyzed by a well-trained radi-
ologist with over 5 years of experience in MRA of the pe-
ripheral vasculature. For this study, CE-MRA data were used
to determine the presence and severity of obstructive
arterial lesions in PAD and to exclude the presence of
obstructive arterial lesions or arterial malformations in the
group of patients with no PAD.Flow analysis
A quantitative ﬂow analysis package (QFlow) included with
the software release (R11.4.14; Philips Medical Systems) of
the MRI hardware was used to analyze the ﬂow data
directly after acquisition. Using this software, a region of
interest (ROI) covering the entire visible cross-section of the
artery of interest was accurately drawn manually using a
modulus image at peak systole and then automatically
propagated to the remaining cardiac phases using an active
contour algorithm. In general, the PA had the smallest
caliber, covering approximately 6 pixels in diameter (i.e.,
approximately 28 pixels in cross-sectional area).7 Although
the peak systolic phase only is sufﬁcient to calculate the
APF, ROIs were propagated to the remaining cardiac phases
to obtain ﬂow wave forms, which were visually analyzed to
ensure that the chosen cardiac phase was, indeed, at peak
systole and to detect possible aliasing effects. If detected,
the measurement was repeated with a sufﬁciently higher
phase encoding velocity.APF analysis
APF was determined in the most symptomatic leg, accord-
ing to the request form completed by the vascular surgeon
Figure 1. Maximum intensity reconstructions of a contrast-enhanced magnetic resonance angiography acquisitions in a patient with
peripheral arterial disease with a signiﬁcant arterial stenosis in the right common femoral artery (CFA), indicated by the arrow. The
predeﬁned locations of the arterial peak ﬂow (APF) measurements are indicated by the proximal CFA, proximal superﬁcial femoral artery
(SFA), and P2-segment of the popliteal artery (PA). The graphics show examples of ﬂow wave forms in this particular patient. The black
dotted line in each graph indicates the level of the APF.
European Journal of Vascular and Endovascular Surgery Volume 48 Issue 2 p. 185e192 August/2014 187in patients with PAD, and in the right leg in patients with no
PAD, or in the unaffected leg in patients without PAD, but
with DVT. If both legs were equally affected in patients with
PAD, the APF of the right leg was used for analysis. Using
CE-MRA data, patients with PAD were divided into two
subgroups: patients with and without relevant arterial ste-
noses in the peripheral arterial tree. A relevant stenosis was
deﬁned as >50% stenosis (i.e., 50% diameter reduction) in
the iliac artery, CFA, SFA, or PA, independent of the
extensiveness and location of the lesion and/or >50% ste-
nosis in at least two of the three main arteries of the lower
leg. Stenosis of the peripheral arterial tree <50% wasconsidered not to be relevant. A comparison of APF values
was made between PAD patients with and without relevant
stenoses in the peripheral arterial tree and patients with no
PAD at the level of the CFA, SFA, and PA. In addition, the
ability to discriminate between patients with and without
PAD at each level was determined. Furthermore, APF values
in patients with PAD with arterial lesions limited to the
lower leg were compared with patients without PAD in
order to determine whether APF measurements are sensi-
tive for outﬂow lesions. The success rates of APF mea-
surements and causes of failure at the distinctive arterial
positions were determined and compared.
Table 2. Arterial peak ﬂow in patients with (PAD) and without
peripheral arterial disease (non-PAD).
PAD Non-PAD
Relevant
stenosis
APF (mL/s)
n No relevant
stenosis
APF (mL/s)
n APF (mL/s) n
CFA 17.9  9.3 212 24.9  9.0 19 30.6  9.1 45
SFA 9.0  6.8 211 15.8  5.5 20 20.2  6.4 48
PA 4.6  3.0 218 8.7  3.8 21 11.3  3.8 45
Note. Values are mean  SD.APF ¼ arterial peak ﬂow;
CFA ¼ common femoral artery; SFA ¼ superﬁcial femoral artery;
PA ¼ popliteal artery.
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Statistical analysis was performed with SPSS (SPSS 16.0;
IBM, Armonk, NY, USA) and STATA version 11.2 (StataCorp,
College Station, TX, USA). Mean values between groups
were tested for statistical signiﬁcance using a t test for in-
dependent samples. The ability of APF measurements to
discriminate between patients with PAD and those withoutFigure 2. Distribution of arterial peak ﬂow values among a patient w
without PAD at the level of the common femoral artery (CFA), superﬁwas compared using receivereoperating characteristic
(ROC) curves and areas under the curve (AUC). Differences
between the AUCs were tested for statistical signiﬁcance
using the method described by Hanley and McNeil,19 which
accounts for the fact that the AUCs were derived from the
same sample of patients. In all analyses, p-values <.05 were
considered to indicate statistical signiﬁcance.RESULTS
Three hundred and seven consecutive patients undergoing
CE-MRA of the peripheral arteries at MUMC as part of a
clinical routine examination between January and
December 2010 were considered eligible for analysis in this
study. The presence of PAD was conﬁrmed by CE-MRA in
259 patients with PAD. Relevant stenoses were present
anywhere within the peripheral arterial tree in 238 out of
259 patients with PAD according to CE-MRA, whereas no
relevant stenoses were found in 21 patients initially diag-
nosed with PAD.ith peripheral arterial disease (PAD) and a population of patients
cial femoral artery (SFA), and popliteal artery (PA).
Figure 3. Receiver operating characteristic (ROC) curves of a PAD
and non-PAD patient population at the level of the common
femoral artery (CFA), superﬁcial femoral artery (SFA), and popliteal
artery (PA).
Table 3. Main causes of failure of arterial peak ﬂow
measurements.
Arterial position Patients
with PAD
Patients
without PAD
Total
CFA 28 (11%) 3 (6%) 31 (10%)
Operator error 10 2 12
Occlusion 14 0 14
Orthopedic prosthesis 4 0 4
SFA 28 (12%) 0 (0%) 28 (9%)
Operator error 2 0 2
Occlusion 24 0 24
Orthopedic prosthesis 2 0 2
PA 20 (8%) 3 (6%) 23 (7%)
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acquired in the preoperative workup of patients scheduled
for reconstructive surgery with lower extremity tissue
serving as the donor site.
APF values in patients with PAD with and without rele-
vant stenoses and in patients without PAD are given in
Table 2. Mean APF values in patients with PAD with rele-
vant stenosis were reduced by 42%, 55%, and 59%
compared with patients without PAD for the CFA, SFA, and
PA, respectively (p < .01 at all levels). Differences between
patients with PAD with and without relevant stenosis were
signiﬁcant at all arterial positions (p < .01), whereas dif-
ferences between patients with PAD without relevant ste-
nosis and patients without PAD were also signiﬁcant
(p ¼ .03, p < .01, and p ¼ 0.01 for the CFA, SFA, and PA,
respectively).
Arterial lesions were limited to the lower leg (i.e., >50%
stenosis in at least two out of the three main arteries of the
lower leg) in 14 patients with PAD. In these patients, APF
was 25.4  9.7 mL/s, 13.6  4.6 mL/s, and 7.6  4.4 mL/s
in the CFA, SFA, and PA, respectively. The APF in these
patients was signiﬁcantly lower compared with patients
without PAD for the SFA (33%, p < .01) and PA (33%,
p < .01), whereas a similar trend was found for the CFA
(17%, p ¼ .07).
The distribution of APF values of the (most) symptomatic
leg of patients with PAD with relevant stenosis and the right
leg of patients without PAD at the level of the CFA, SFA, and
PA is depicted graphically in Fig. 2. In general, APF values in
patients with PAD were lower than in patients without PAD,
although some overlap exists. Relative differences between
patients with PAD and those without were larger if the
measurement was performed more distally within the pe-
ripheral arterial tree.
The discriminative ability of APF measurements in the
CFA, SFA, and PA is presented in Fig. 3. These ROC curves
show that with measurements at the level of the SFA and
PA a sensitivity of about 90% can be achieved with a cor-
responding false-positive rate of 20%, whereas at the level
of the CFA sensitivity is only about 70% with a false-positive
of 20%. The AUC at the level of the CFA was 0.84 with a 95%
conﬁdence interval (CI) between 0.78 and 0.89. At the level
of the SFA and PA, AUCs were 0.92 (95% CI 0.88e0.96) and
0.92 (95% CI 0.88e0.95), respectively. The AUC at the level
of the CFA was signiﬁcantly lower compared with AUCs at
the level of the SFA and PA, whereas no statistically sig-
niﬁcant difference was found between the level of the SFA
and PA.
Causes of failure of APF measurements are given in
Table 3. Operator errors mainly consisted of incorrect
localization of the slices of the ﬂow measurements.Operator error 2 2 4
Occlusion 12 0 12
Orthopedic prosthesis 4 1 5
Bypass 2 0 2
Total 76 (10%) 6 (4%) 82 (9%)
Note. PAD ¼ peripheral arterial disease; CFA ¼ common femoral
artery; SFA ¼ superﬁcial femoral artery; PA ¼ popliteal artery.DISCUSSION
It would be clinically desirable to have a standardized
arterial position to measure the APF, preferably indepen-
dent of the location of obstructive arterial lesions, with
well-known reference values and a good ability todifferentiate between diseased and healthy arterial vascu-
lature. The most suitable location for this purpose was ex-
pected to be the PA, as this is the most distally located large
conduit artery of the peripheral arterial tree and therefore
situated distal to the majority of the obstructive arterial
lesions. According to the results of this study, the APF ac-
quired in the PA does, indeed, show the largest differences
between patients with PAD and those without it (i.e., 59%
lower APF values in patients with PAD), a high discrimina-
tive ability (AUC ¼ 0.92), and has the highest success rate of
the measurement (up to 92% in patients with PAD).
Objective assessment of the functional consequences of
stenoses and occlusions in the peripheral arterial tree is a
necessity in diagnosis and longitudinal follow-up or therapy
monitoring of patients with PAD. Currently, the ABI
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applied functional measurement used for diagnosis and
therapy monitoring.4,20,21 However, ABI measurements are
hampered by poor reproducibility and cannot be deter-
mined accurately in patients with heavily calciﬁed ar-
teries.7,22e24 Other known techniques for determining
vascular function are Doppler-based ﬂow measurements,
plethysmography, skin perfusion pressure measurements,
positron emission tomography, contrast-enhanced ultra-
sound, and intra-arterial pressure and/or ﬂow measure-
ments.25e34 However, these techniques may lack the spatial
resolution or coverage to directly measure the effect of
vascular adaptations (e.g., collateral vessel formation or
changes in microcirculation), or are unfavorable for
repeated measurements, for instance in the context of
therapy monitoring owing to invasiveness, use of ionizing
radiation, or large interobserver variability.8
MRA has established itself as a highly accurate noninva-
sive diagnostic imaging method, and is widely applied in the
diagnosis and treatment planning of PAD.1e4 Owing to the
progressive nature of PAD, increasing numbers of patients
with PAD undergo multiple MRA examinations throughout
their life. For these patients, MRI can also be used to obtain
objective functional vascular information, for example by
measuring APF. The APF is deﬁned as the maximum systolic
ﬂow, and is an attractive arterial ﬂow measure, as it is an
important determinant of systolic blood pressure,35 which
has previously shown relatively large differences between
patients with PAD and controls, and proved highly repro-
ducible.5e7,16
One of the strengths of other functional tests, for
example ABI measurements, is a high degree of standardi-
zation, meaning that, for example, the ABI is measured at
the same location with the same technique for every pa-
tient. Such a standardized protocol is a necessity for func-
tional measurements to be suitable for longitudinal follow-
up or therapy monitoring in patients. As APF measurements
are relatively new and not yet widely applied, no such
standardized protocol exists; reference values are also un-
known. Although APF measurements are relatively quick, it
would be highly desirable to have a single, predeﬁned
location at which to measure the APF in all patients with
PAD, a location where the ability to differentiate between
diseased and normal vasculature is best.
A standardized approach in which the APF was measured
in the proximal CFA, proximal SFA ,and P2 segment of the
PA in patients with PAD, independent of the location of
obstructive arterial lesions, and in patients without PAD has
been demonstrated in this study. At all arterial levels, the
mean APF values in patients with PAD were signiﬁcantly
lower compared with patients without PAD. The largest
decrease in APF was found at the level of the PA in patients
with PAD with a clinically relevant stenosis, where the
average APF was 59% lower than that of patients without
PAD. A simple explanation for this ﬁnding is that ﬂow in PA
reﬂects all proximal obstructive arterial lesions. Interest-
ingly, APF measured in the SFA and PA are both sensitive forproximal disease, as well as disease distal to the position of
the measurement.
A distinction was made between patients with PAD with
and without relevant stenoses, as those without relevant
stenosis were expected to have higher APF values, while
therapeutic options in these patients differ from those pa-
tients with relevant stenosis. The results of this study
conﬁrm this assumption, as APF in patients with PAD with
relevant stenoses was signiﬁcantly lower than in those
without stenoses. Nevertheless, the APF in patients with
PAD without relevant stenoses was also signiﬁcantly lower
compared with the group of patient without PAD. Appar-
ently, a stenosis of <50%, which was considered to be non-
relevant, still results in a reduction of APF, although it is
much less pronounced than in patients with relevant ste-
noses. Further studies will be needed to correlate the de-
gree of stenosis with a reduction in APF, as this was beyond
the scope of this preliminary study. Owing to the large
differences in APF between patients with PAD and those
without, the discriminative ability of APF measurements
was excellent. The largest AUC was found at the level of the
PA (0.93) again, although the difference compared with the
SFA (0.92) was small. The average success rate of APF
measurements was high (91%, on average, for all patients in
this study) and best at the level of the PA in patients with
PAD and in those without.
The SFA and PA are both excellent positions in which to
measure the APF, independent from the location of
obstructive arterial lesions. Nevertheless, it would be pref-
erable to measure the APF in the PA, as results at this
position were only slightly, but consistently, better, and the
PA is situated distal to the majority of the obstructive
arterial lesions (i.e., iliac arteries, CFA, SFA, and/or P1/2
segment of the PA).
There are some limitations of this study. Only patients
with PAD scheduled for MRA were included. Although this
resulted in a select study population, this population was
considered to be clinically the most relevant as far as APF
measurements are concerned, as, owing to the limited
availability of MRI systems or magnet time, and associated
costs, MRI-based APF measurements are not (yet) suitable
for screening. Also, as the selected population comprised
consecutive patients undergoing CE-MRA, it was a clinically
representative group as far as disease severity is concerned.
Nevertheless, this implies that the current ﬁndings do not
necessarily apply to all patients with PAD.
The group of patients with no PAD and who were used as
controls were free from PAD according to CE-MRA and
anamnesis, but not free from vascular disease, as the ma-
jority of these patients had DVT. Nevertheless, APF mea-
surements of these patients were comparable with healthy
controls from previous studies that used the same
method.5e7 Also, all angiographic readings were performed
by one radiologist, so potential bias cannot be excluded.
Nevertheless, we previously found that the inter-reader
reproducibility of MRA and APF measurements are both
excellent.5
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level of the main arteries of the lower leg as the current
spatial resolution would have been insufﬁcient to accurately
measure the ﬂow in these small arteries.14,36,37 However,
increasing the spatial resolution would have resulted in
unsatisfactory acquisition times for clinical practice. Yet, as
the results have shown, APF measurements at the level of
the SFA and PA proved sensitive for arterial stenosis in the
lower leg.
To conclude, the APF measured in the PA shows the
largest difference between patients with PAD and those
without, the best discriminative ability, and the highest
success rates compared with measurements in the CFA or
SFA, even though differences in the SFA are small. There-
fore, the PA is the most suitable position for a standardized
measurement of the APF in patients with PAD in order to
obtain relevant functional information about vascular sta-
tus. Given the optimal position of APF measurement, future
studies can now be performed to relate the clinical status,
morphological presentation, and APF to its clinical role,
particularly for the evaluation of responses due to
treatment.FUNDING
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